David R. Gandara

54.6k total citations · 8 hit papers
648 papers, 29.8k citations indexed

About

David R. Gandara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, David R. Gandara has authored 648 papers receiving a total of 29.8k indexed citations (citations by other indexed papers that have themselves been cited), including 439 papers in Oncology, 418 papers in Pulmonary and Respiratory Medicine and 191 papers in Molecular Biology. Recurrent topics in David R. Gandara's work include Lung Cancer Treatments and Mutations (362 papers), Lung Cancer Research Studies (174 papers) and Lung Cancer Diagnosis and Treatment (129 papers). David R. Gandara is often cited by papers focused on Lung Cancer Treatments and Mutations (362 papers), Lung Cancer Research Studies (174 papers) and Lung Cancer Diagnosis and Treatment (129 papers). David R. Gandara collaborates with scholars based in United States, Canada and Germany. David R. Gandara's co-authors include Primo N. Lara, Philip C. Mack, Karen Kelly, John J. Crowley, Kathy S. Albain, Kari Chansky, John Crowley, Paul H. Gumerlock, Robert B. Livingston and Derick Lau and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David R. Gandara

630 papers receiving 29.0k citations

Hit Papers

Phase III Study Comparing Cisplatin Plus Gemcitabi... 1995 2026 2005 2015 2008 2000 2009 2001 1995 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
    2008 2.5k citations Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology profile →
  2. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
    2000 1.1k citations David R. Gandara et al. Journal of Clinical Oncology profile →
  3. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
    2009 999 citations Kathy S. Albain, David R. Gandara et al. profile →
  4. Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
    2001 923 citations Karen Kelly, Paul A. Bunn et al. Journal of Clinical Oncology profile →
  5. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    1995 633 citations Kathy S. Albain, John J. Crowley et al. Journal of Clinical Oncology profile →
  6. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    2002 551 citations David R. Gandara, Paul H. Gumerlock et al. profile →
  7. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
    2018 271 citations Oliver A. Zill, Kimberly C. Banks et al. Clinical Cancer Research profile →
  8. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
    2022 128 citations Mary W. Redman, Katherine Minichiello et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David R. Gandara United States 78 18.4k 17.0k 8.1k 4.7k 2.5k 648 29.8k
Joan H. Schiller United States 72 19.1k 1.0× 19.9k 1.2× 9.8k 1.2× 4.6k 1.0× 1.4k 0.6× 348 31.0k
Corey J. Langer United States 73 16.9k 0.9× 17.1k 1.0× 5.7k 0.7× 3.1k 0.7× 3.1k 1.3× 563 28.2k
Giorgio V. Scagliotti Italy 71 19.6k 1.1× 17.1k 1.0× 8.4k 1.0× 5.3k 1.1× 2.7k 1.1× 480 29.7k
David H. Johnson United States 61 18.4k 1.0× 15.1k 0.9× 5.7k 0.7× 3.3k 0.7× 2.2k 0.9× 242 26.2k
Egbert F. Smit Netherlands 84 18.0k 1.0× 14.8k 0.9× 7.4k 0.9× 4.0k 0.9× 1.7k 0.7× 692 29.3k
Kazuhiko Nakagawa Japan 80 20.8k 1.1× 22.1k 1.3× 9.9k 1.2× 4.4k 0.9× 2.3k 0.9× 815 32.3k
Nagahiro Saijo Japan 68 13.4k 0.7× 16.3k 1.0× 9.1k 1.1× 3.5k 0.7× 1.5k 0.6× 557 25.4k
Everett E. Vokes United States 95 15.5k 0.8× 19.2k 1.1× 9.6k 1.2× 3.2k 0.7× 7.6k 3.0× 774 36.3k
D. Ross Camidge United States 77 16.9k 0.9× 15.0k 0.9× 8.6k 1.1× 4.6k 1.0× 1.4k 0.6× 539 24.2k
Eric K. Rowinsky United States 81 9.6k 0.5× 18.5k 1.1× 12.1k 1.5× 3.6k 0.8× 3.8k 1.5× 396 32.1k

Countries citing papers authored by David R. Gandara

Since Specialization
Citations

This map shows the geographic impact of David R. Gandara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Gandara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Gandara more than expected).

Fields of papers citing papers by David R. Gandara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Gandara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Gandara. The network helps show where David R. Gandara may publish in the future.

Co-authorship network of co-authors of David R. Gandara

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Gandara. A scholar is included among the top collaborators of David R. Gandara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Gandara. David R. Gandara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Bob T., Jeffrey Clarke, Enriqueta Felip, et al.. (2024). Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.. Journal of Clinical Oncology. 42(16_suppl). 8512–8512. 8 indexed citations
2.
Mack, Philip C., Jieling Miao, Mary W. Redman, et al.. (2022). Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403). Clinical Cancer Research. 28(17). 3752–3760. 31 indexed citations
3.
Leighl, Natasha B., Mary W. Redman, Naiyer A. Rizvi, et al.. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer. 9(8). e002973–e002973. 38 indexed citations
4.
Zill, Oliver A., Kimberly C. Banks, Stephen R. Fairclough, et al.. (2018). The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clinical Cancer Research. 24(15). 3528–3538. 271 indexed citations breakdown →
5.
Floc’h, Nicolas, Matthew J. Martin, Jonathan W. Riess, et al.. (2018). Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Molecular Cancer Therapeutics. 17(5). 885–896. 85 indexed citations
6.
Tomlinson, Benjamin, James A. Thomson, John S. Bomalaski, et al.. (2015). Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research. 21(11). 2480–2486. 66 indexed citations
7.
Fahrmann, Johannes F., Kyoungmi Kim, Brian C. DeFelice, et al.. (2015). Investigation of Metabolomic Blood Biomarkers for Detection of Adenocarcinoma Lung Cancer. Cancer Epidemiology Biomarkers & Prevention. 24(11). 1716–1723. 59 indexed citations
8.
Redman, Mary W., John J. Crowley, Roy S. Herbst, Fred R. Hirsch, & David R. Gandara. (2012). Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819. Clinical Cancer Research. 18(15). 4004–4012. 38 indexed citations
9.
Kummar, Shivaani, Jiuping Ji, Robert J. Morgan, et al.. (2012). A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. Clinical Cancer Research. 18(6). 1726–1734. 155 indexed citations
10.
Tarhini, Ahmad A., Paul Frankel, Kim Margolin, et al.. (2011). Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. Clinical Cancer Research. 17(20). 6574–6581. 62 indexed citations
11.
Hirsch, Fred R., Murry W. Wynes, David R. Gandara, & Paul A. Bunn. (2010). The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer. Clinical Cancer Research. 16(20). 4909–4911. 58 indexed citations
12.
Pisters, Katherine M.W., Eric Vallières, John J. Crowley, et al.. (2010). Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial. Journal of Clinical Oncology. 28(11). 1843–1849. 167 indexed citations
13.
Scagliotti, Giorgio V., Purvish Parikh, Joachim von Pawel, et al.. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(21). 3543–3551. 2487 indexed citations breakdown →
14.
Kelly, Karen, Kari Chansky, Laurie E. Gaspar, et al.. (2008). Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023. Journal of Clinical Oncology. 26(15). 2450–2456. 421 indexed citations
15.
Raz, Dan J., M. Ray, Biao He, et al.. (2008). A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma. Clinical Cancer Research. 14(17). 5565–5570. 60 indexed citations
16.
Schultheis, Anne M., Georg Lurje, Katrin E. Rhodes, et al.. (2008). Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab. Clinical Cancer Research. 14(22). 7554–7563. 137 indexed citations
17.
Gautschi, Oliver, Clifford G. Tepper, Phillip R. Purnell, et al.. (2008). Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer. Cancer Research. 68(7). 2250–2258. 67 indexed citations
18.
Gautschi, Oliver, Philip C. Mack, Angela M. Davies, Primo N. Lara, & David R. Gandara. (2006). Aurora Kinase Inhibitors: A New Class of Targeted Drugs in Cancer. Clinical Lung Cancer. 8(2). 93–98. 19 indexed citations
19.
Mack, Philip C., et al.. (2004). Enhancing the anticancer activity of paclitaxel through cyclin-dependent kinase inhibition. Cancer Research. 64. 1254–1254. 1 indexed citations
20.
Lara, Primo N., Frederick J. Meyers, Carl Gray, et al.. (2002). HER‐2/neu is overexpressed infrequently in patients with prostate carcinoma. Cancer. 94(10). 2584–2589. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joan H. Schiller Breakdown of academic impact, for papers by Corey J. Langer Breakdown of academic impact, for papers by Giorgio V. Scagliotti Breakdown of academic impact, for papers by David H. Johnson Breakdown of academic impact, for papers by Egbert F. Smit Breakdown of academic impact, for papers by Kazuhiko Nakagawa Breakdown of academic impact, for papers by Nagahiro Saijo Breakdown of academic impact, for papers by Everett E. Vokes Breakdown of academic impact, for papers by D. Ross Camidge Breakdown of academic impact, for papers by Eric K. Rowinsky
Rankless by CCL
2026